Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Annotating MYC status with 89Zr-transferrin imaging.

Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS.

Nat Med. 2012 Oct;18(10):1586-91. doi: 10.1038/nm.2935. Epub 2012 Sep 23.

2.

89Zr-Desferrioxamine B-Transferrin.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2013 Apr 1 [updated 2013 Jun 6].

3.

89Zr radiochemistry for positron emission tomography.

Severin GW, Engle JW, Barnhart TE, Nickles RJ.

Med Chem. 2011 Sep;7(5):389-94. Review.

4.

PET tracers based on Zirconium-89.

Zhang Y, Hong H, Cai W.

Curr Radiopharm. 2011 Apr;4(2):131-9. Review.

5.

PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.

Deri MA, Zeglis BM, Francesconi LC, Lewis JS.

Nucl Med Biol. 2013 Jan;40(1):3-14. doi: 10.1016/j.nucmedbio.2012.08.004. Epub 2012 Sep 19. Review.

6.

Review on production of 89Zr in a medical cyclotron for PET radiopharmaceuticals.

Kasbollah A, Eu P, Cowell S, Deb P.

J Nucl Med Technol. 2013 Mar;41(1):35-41. doi: 10.2967/jnmt.112.111377. Epub 2013 Jan 17. Review.

7.

Positron emission tomography for prostate, bladder, and renal cancer.

Schöder H, Larson SM.

Semin Nucl Med. 2004 Oct;34(4):274-92. Review.

PMID:
15493005
8.

Positron emission tomography and computer tomography (PET/CT) in prostate, bladder, and testicular cancers.

Zouhair A, Ozsahin M, Schaffer M, Albrecht S, Camus F, Jichlinski P, Mirimanoff RO, Bischof Delaloye A, Meuwly JY, Prior JO.

Curr Med Chem. 2010;17(23):2492-502. Review.

PMID:
20491646
9.

Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.

Evans MJ.

Cancer Discov. 2012 Nov;2(11):985-94. doi: 10.1158/2159-8290.CD-12-0178. Epub 2012 Oct 5. Review.

Supplemental Content

Support Center